Should I buy or sell Sera Prognostics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SERA shares. View SERA analyst ratings or view top-rated stocks .

What is Sera Prognostics' stock price target for 2024?

2 Wall Street analysts have issued 12-month price targets for Sera Prognostics' shares. Their SERA share price targets range from $2.75 to $2.75. On average, they expect the company's stock price to reach $2.75 in the next twelve months. This suggests that the stock has a possible downside of 71.9%. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts .

How have SERA shares performed in 2024?

Sera Prognostics' stock was trading at $5.98 at the start of the year. Since then, SERA shares have increased by 63.7% and is now trading at $9.79. View the best growth stocks for 2024 here .

Are investors shorting Sera Prognostics?

Sera Prognostics saw a increase in short interest in March. As of March 31st, there was short interest totaling 198,600 shares, an increase of 71.5% from the March 15th total of 115,800 shares. Based on an average daily volume of 245,400 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.2% of the company's stock are short sold. View Sera Prognostics' Short Interest .

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SERA earnings forecast .

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) released its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative trailing twelve-month return on equity of 45.74%.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (0.06%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt. View institutional ownership trends .

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:SERA

Sera Prognostics (SERA) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free SERA Stock Alerts

$9.79

+0.11 (+1.14%)

(As of 04/18/2024 ET)

Compare

Today's Range: $9.60
▼
$9.94
50-Day Range: $8.47
▼
$11.25
52-Week Range: $1.52
▼
$11.32

Volume: 66,950 shs
Average Volume: 236,511 shs
Market Capitalization: $317.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.75

Get Sera Prognostics alerts:

Sera Prognostics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 71.9% Downside
$2.75 Price Target
Short Interest: Healthy
1.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.60
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.26 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.94) to ($0.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

828th out of 918 stocks

Medical Laboratories Industry

17th out of 19 stocks

1.3

Analyst's Opinion

Consensus Rating
Sera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Sera Prognostics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.15% of the float of Sera Prognostics has been sold short.
Short Interest Ratio / Days to Cover
Sera Prognostics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sera Prognostics has recently increased by 71.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sera Prognostics does not currently pay a dividend.
Dividend Growth
Sera Prognostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SERA.

3.7

News and Social Media Coverage

News Sentiment
Sera Prognostics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Sera Prognostics this week, compared to 1 article on an average week.
Search Interest
5 people have searched for SERA on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Sera Prognostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,255,192.00 in company stock.
Percentage Held by Insiders
15.60% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sera Prognostics are expected to grow in the coming year, from ($0.94) to ($0.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sera Prognostics is -8.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sera Prognostics is -8.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sera Prognostics has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

About Sera Prognostics Stock (NASDAQ:SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SERA Stock News Headlines

March 29, 2024 | insidertrades.com

Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells 24,474 Shares of Stock

March 27, 2024 | insidertrades.com

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $75,822.04 in Stock

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 16, 2024 | finance.yahoo.com

EarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and Technology

March 29, 2024 | finance.yahoo.com

Chief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA)

March 27, 2024 | finance.yahoo.com

Chief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)

March 27, 2024 | finance.yahoo.com

Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA)

March 21, 2024 | finanznachrichten.de

Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial Results

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 21, 2024 | finance.yahoo.com

Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript

March 20, 2024 | investorplace.com

SERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023

March 20, 2024 | benzinga.com

Sera Prognostics: Q4 Earnings Insights

March 20, 2024 | finance.yahoo.com

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

March 20, 2024 | finance.yahoo.com

Sera Prognostics Inc Reports Modest Revenue Growth Amid Operational Streamlining

March 19, 2024 | benzinga.com

Sera Prognostics's Earnings Outlook

March 19, 2024 | markets.businessinsider.com

Sera Prognostics A is about to announce its earnings — here's what to expect

March 19, 2024 | finance.yahoo.com

Companies Like Sera Prognostics (NASDAQ:SERA) Are In A Position To Invest In Growth

March 4, 2024 | prnewswire.com

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

February 29, 2024 | prnewswire.com

Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference

February 22, 2024 | benzinga.com

Sera Prognostics Stock (NASDAQ:SERA), Short Interest Report

February 15, 2024 | msn.com

Top Growth Stocks Under $50 for February 2024

January 11, 2024 | msn.com

Sera Prognostics, Atreca spike after Baker Bros investments

January 4, 2024 | finance.yahoo.com

PRISM MarketView Launches Emerging Women’s Health Index

January 3, 2024 | finance.yahoo.com

EarlyDiagnostics, Inc. Appoints Gregory C. Critchfield, M.D. M.S., as Co-CEO

December 11, 2023 | finance.yahoo.com

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

December 7, 2023 | finance.yahoo.com

While institutions invested in Sera Prognostics, Inc. (NASDAQ:SERA) benefited from last week's 183% gain, retail investors stood to gain the most

December 7, 2023 | msn.com

Why Is Preterm Birth Risk Kit Focused Sera Prognostics Stock Trading Higher Today?

See More Headlines

Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:SERA
CUSIP: N/A
CIK: 1534969
Web: www.seraprognostics.com
Phone: 801-990-0520
Fax: N/A
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.75
High Stock Price Target: $2.75
Low Stock Price Target: $2.75
Potential Upside/Downside: -71.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,240,000.00
Net Margins: -11,843.79%
Pretax Margin: -11,843.79%
Return on Equity: -45.74%
Return on Assets: -37.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.51
Quick Ratio: 2.51

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 1,024.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.21 per share
Price / Book: 4.43

Miscellaneous

Outstanding Shares: 32,430,000
Free Float: 27,368,000
Market Cap: $317.49 million
Optionable: Not Optionable
Beta: 1.49

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Ms. Evguenia Lindgardt M.B.A. (Age 50)
President, CEO & Director
Comp: $37.5k
Dr. Gregory C. Critchfield M.D. (Age 71)
M.S., Executive Director
Comp: $790.74k
Dr. Steven W. Graves
Co-Founder and Co-Chairman of The Scientific Advisory Board
Dr. M. Sean Esplin M.D.
Co-Founder and Co-Chairman of Scientific Advisory Board
Mr. Austin Aerts
Chief Financial Officer??
Dr. John J. Boniface Ph.D. (Age 62)
Chief Scientific Officer
Comp: $386.69k
Mr. Robert G. Harrison (Age 58)
Chief Information Officer
Comp: $384.18k
Mr. Benjamin G. Jackson J.D. (Age 45)
General Counsel
Comp: $410.75k
Dr. Paul Kearney Ph.D. (Age 56)
Chief Data Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SERA shares.
View SERA analyst ratings or view top-rated stocks.
What is Sera Prognostics' stock price target for 2024?: 2 Wall Street analysts have issued 12-month price targets for Sera Prognostics' shares. Their SERA share price targets range from $2.75 to $2.75. On average, they expect the company's stock price to reach $2.75 in the next twelve months. This suggests that the stock has a possible downside of 71.9%.
View analysts price targets for SERA or view top-rated stocks among Wall Street analysts.
How have SERA shares performed in 2024?: Sera Prognostics' stock was trading at $5.98 at the start of the year. Since then, SERA shares have increased by 63.7% and is now trading at $9.79.
View the best growth stocks for 2024 here.
Are investors shorting Sera Prognostics?: Sera Prognostics saw a increase in short interest in March. As of March 31st, there was short interest totaling 198,600 shares, an increase of 71.5% from the March 15th total of 115,800 shares. Based on an average daily volume of 245,400 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.2% of the company's stock are short sold.
View Sera Prognostics' Short Interest.
When is Sera Prognostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SERA earnings forecast.

How were Sera Prognostics' earnings last quarter?: Sera Prognostics, Inc. (NASDAQ:SERA) released its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative trailing twelve-month return on equity of 45.74%.
When did Sera Prognostics IPO?: Sera Prognostics (SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share.
Who are Sera Prognostics' major shareholders?: Sera Prognostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (0.06%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt.
View institutional ownership trends.
How do I buy shares of Sera Prognostics?: Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SERA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial